Compare
Pyxis Oncology, Inc. vs CV Sciences, Inc. vs Tonix Pharmaceuticals Holding Corp. vs Evommune, Inc.
| Latest fiscal year | Pyxis Oncology, Inc. PYXS | CV Sciences, Inc. CVSI | Tonix Pharmaceuticals Holding Corp. TNXP | Evommune, Inc. EVMN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $13.86M | $13.79M | $13.11M | $13.00M |
| Revenue growth (YoY) | -14.2% | -12.2% | +29.8% | +85.7% |
| Gross margin | 82.8% (computed) | 49.0% | 49.3% (computed) | n/a |
| Operating margin | -609.2% | -3.4% | -959.1% | -623.6% |
| Net margin | -574.5% | -6.9% | -946.2% | -529.8% |
| Net income | -$79.62M | -$958.0K | -$124.02M | -$68.87M |
| EPS (Diluted) | -$1.28 | -$0.01 | -$14.57 | -$11.22 |
| Operating cash flow | -$63.50M | -$407.0K | -$99.84M | -$76.44M |
| Free cash flow | -$63.51M | -$516.0K | -$103.21M | -$76.68M |
| Cash & equivalents | $15.42M | n/a | $207.64M | $44.06M |
| Total assets | $91.52M | $6.96M | $277.17M | $224.95M |
| Total liabilities | $38.11M | $5.49M | $32.02M | $19.38M |
| Shareholders' equity | $53.41M | $1.47M | $245.15M | $205.57M |
| Return on year-end equity | -149.1% | -65.3% | -50.6% | -33.5% |
| Shares outstanding | 62.69M | 184.26M | 12.79M | 31.52M |
Revenue, most recent five fiscal years
| Fiscal year | Pyxis Oncology, Inc. | CV Sciences, Inc. | Tonix Pharmaceuticals Holding Corp. | Evommune, Inc. |
|---|---|---|---|---|
| Latest | $13.86M Ended 2025-12-31 | $13.79M Ended 2025-12-31 | $13.11M Ended 2025-12-31 | $13.00M Ended 2025-12-31 |
| 1 year earlier | $16.15M Ended 2024-12-31 | $15.71M Ended 2024-12-31 | $10.09M Ended 2024-12-31 | $7.00M Ended 2024-12-31 |
| 2 years earlier | n/a | $16.00M Ended 2023-12-31 | $7.77M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $16.20M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $20.05M Ended 2021-12-31 | n/a | n/a |